🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cancer care and research is an ever-evolving field, and our work reminds us that truly impactful progress can be made by forging new paths. #ThursdayThoughts

In this phase 1 trial of personalised #neoantigen-specific T cell therapy #BNT221 for metastatic #melanoma patients refractory to PD-1 and CTLA-4 inhibitors, the therapy was safe with preliminary clinical activity and T cell responses. nature.com/articles/s4159…

Review NatureRevClinOncol Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach nature.com/articles/s4157…

We developed a 3-gene signature to identify tumor-specific CD8 TIL, i.e. the cells targeted by #immunotherapy, from #singlecell data. Out now in Nature Communications. All data & code are public. Please use it! #WomenInSTEM #science #research #datascience #AI nature.com/articles/s4146…

Perhaps with the figure too: little knowledge + #ignorance = highest #confidence extensive knowledge/expert = moderate confidence In other words, people with the loudest #voice often have the least knowledge but have their confidence pumped by ignorance.

Dear Trainees, bookmark this👇 Dr. Marco Ruella Society for Immunotherapy of Cancer teaching us how to give a good talk, by purposefully giving a *bad* talk! 👏😉 - Lighter the better - Less is more - Consistent font - Large font size (>=18) - Careful with animations: friends sometimes (to help introduce

A major update to the CONSORT reporting guidance for clinical trials was published last week. 📌 CONSORT 2025 replaces all previous versions and should be used from now on. So what’s new and what’s different? 1/7 #MethodologyMonday #116 (COI - I am a co-author)

Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" Penn Medicine @nejm #immunotherapy nejm.org/doi/full/10.10…

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Live from #ASCO25, Kimberly Ward (Kimberly Ward, MPH), Research Project Manager Moffitt Cancer Center, shares the results of a study on first-line nivo-rela in advanced or resectable #melanoma, highlighting real-world outcomes and the potential role of B7-H3 in resistance. Lilit Karapetyan

New #JITC commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy bit.ly/4jwhLmm elizabeth buchbinder Kim Margolin Allison Betof Warner, MD, PhD

Cómo ha ido vuestro domingo? 🥲

🏆 #NationsLeague-Champions 2025: Congrats, Portugal! 🙌🤩🎉 #Portugal | #POR | #PORESP I.E. 5:3

Portugal 🇵🇹 , before CR7: ❌ Played 3/17 World Cups (3rd in 1966) ❌ Played 3/11 Euro Cups ❌ No title Portugal 🇵🇹 , after CR7: ✅ Played 5/5 World Cups ✅ Played 6/6 Euro Cups ✅ Euro 2016 Champion ✅ Nations League Champion in 2019 and 2025. Congrats LEGEND ❤️

The Allianz Arena in Munich echoed with chants of “PEPE! PEPE!” x.com/WtXejo8XAT8198…

❤️Cristiano Ronaldo

Leadership isn't measured by how many followers you have. It's gauged by how may lives you improve. Selfish leaders divide people to advance personal agendas. Servant leaders unite people to achieve common goals. The best leaders are those who bring out the best in others.

The people who dominate the conversation often have the least to say. Being the loudest voice in the room doesn’t gain respect. It crowds out the contributions of those who speak at a lower volume. It’s better to leave people wanting to hear more than wishing they’d heard less.

A final piece of advice from Holly Butcher - written the day before she passed away from cancer at just 27: “It’s a strange thing knowing you’re going to die young. At 26, I thought I had time… To fall in love. Start a family. Grow old. But cancer doesn’t care about plans.